Product news

Share this article:

Schering-Plough submitted a NDA for Zegerid (omeprazole/sodium bicarbonate), in the dosage strength of 20 mg, as a branded over-the-counter (OTC) product to treat frequent heartburn. The NDA was submitted under the terms of a license agreement with Santarus, of San Diego, which was signed in October 2006 for the exclusive US/Canadian rights to market OTC Zegerid proton pump inhibitor (PPI) products using Santarus' technology.

The FDA has approved Auriga Laboratories' Liquadd (dextroamphetamine sulfate), indicated for the treatment of attention deficit disorder with hyperactivity (ADHD). Liquadd will be launched during the second-quarter of 2008. The ADHD market is valued at over $3.5 billion dollars, with approximately 35 million prescriptions written annually.

Spectrum Pharmaceuticals said it received FDA marketing approval for Levoleucovorin for Injection, indicated after high-dose methotrexate therapy in patients with osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination or inadvertent overdose of folic acid antagonists. Spectrum expects its commercial launch of the treatment by June 2008.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.